Unlocking the Glioblastoma Enigma: Exploring PD-L1 (Programmed Death-Ligand 1) and IDH1 (Isocitrate Dehydrogenase-1) Expression and Their Immunotherapeutic Implications.

导出 LinkOut

翻译打印收藏纠错

第一作者： Syeda Iqra,Mushir

第一单位： Histopathology, Shaheed Zulfiqar Ali Bhutto Medical University/Pakistan Institute of Medical Sciences (PIMS), Islamabad, PAK.

作者： Syeda Iqra,Mushir ^[1] ; Summaya S,Chaudry ^[1] ; Henna,Azmat ^[2] ; Areeba,Masood ^[1] ; Momina,Habib ^[1] ; Ahmareen K,Sheikh ^[1]

作者单位： Histopathology, Shaheed Zulfiqar Ali Bhutto Medical University/Pakistan Institute of Medical Sciences (PIMS), Islamabad, PAK. ^[1] Pathology, Federal Government Polyclinic, Islamabad, PAK. ^[2]

关键词 bevacizumab glioblastoma multiforme (gbm)glioma idh1 mutation immune microenvironment immunohistochemistry immunotherapy nivolumab pd-l1 expression tumor proportion score (tps)

DOI 10.7759/cureus.76920

PMID 39906459

发布时间 2025-02-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cureus

2025年17卷1期

e76920页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Unlocking the Glioblastoma Enigma: Exploring PD-L1 (Programmed Death-Ligand 1) and IDH1 (Isocitrate Dehydrogenase-1) Expression and Their Immunotherapeutic Implications.

Cureus

相似文献

Cureus

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Unlocking the Glioblastoma Enigma: Exploring PD-L1 (Programmed Death-Ligand 1) and IDH1 (Isocitrate Dehydrogenase-1) Expression and Their Immunotherapeutic Implications.

Cureus

相似文献

Cureus

相关期刊

检索历史清除